Back to results
US 2018/0008593 A1Published application
Dosage form containing oxycodone and naloxone
AssigneePurdue Pharma L.P.
InventorsPetra LEYENDECKER, Michael HOPP, Kevin SMITH
Life of this patent
Estimating the term…
Abstract
The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.
Claims47
1-25. (canceled)
A method for treating pain comprising administering to a patient in need thereof, who is opioid-dependent, more than one sustained release oral dosage form per day, the dosage form comprising:
- oxycodone or a pharmaceutically acceptable salt thereof;
- and
- naloxone or a pharmaceutically acceptable salt thereof;
- wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in each dosage form in a weight ratio of 2:1;
- and
- wherein the amount of the oxycodone or pharmaceutically acceptable salt thereof administered is from 80 mg up to 160 mg per day.
3 more elements
A method for treating pain comprising administering twice-a-day to a patient in need thereof, who is opioid-dependent, a sustained release oral dosage form comprising:
- about 40 mg of oxycodone or a pharmaceutically acceptable salt thereof;
- and
- about 20 mg of naloxone or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.